194 related articles for article (PubMed ID: 32578360)
21. Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily.
Wrigley JD; Gavory G; Simpson I; Preston M; Plant H; Bradley J; Goeppert AU; Rozycka E; Davies G; Walsh J; Valentine A; McClelland K; Odrzywol KE; Renshaw J; Boros J; Tart J; Leach L; Nowak T; Ward RA; Harrison T; Andrews DM
ACS Chem Biol; 2017 Dec; 12(12):3113-3125. PubMed ID: 29131570
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a potent hedgehog pathway inhibitor capable of activating caspase8-dependent apoptosis.
Chen Q; Zhang H; Wu M; Wang Q; Luo L; Ma H; Zhang X; He S
J Pharmacol Sci; 2018 Jul; 137(3):256-264. PubMed ID: 30064819
[TBL] [Abstract][Full Text] [Related]
23. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
[TBL] [Abstract][Full Text] [Related]
24. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.
Dubey AK; Dubey S; Handu SS; Qazi MA
J Postgrad Med; 2013; 59(1):48-50. PubMed ID: 23525058
[TBL] [Abstract][Full Text] [Related]
25. USP28 promotes aerobic glycolysis of colorectal cancer by increasing stability of FOXC1.
Liu Z; Chen M; Xu X; Zhang L; Pan Y; Chen D
Acta Biochim Pol; 2021 Jun; 68(4):633-639. PubMed ID: 34106567
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer.
Ishii A; Shigemura K; Kitagawa K; Sung SY; Chen KC; Yi-Te C; Liu MC; Fujisawa M
Anticancer Res; 2020 Sep; 40(9):5107-5114. PubMed ID: 32878799
[TBL] [Abstract][Full Text] [Related]
27. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
[TBL] [Abstract][Full Text] [Related]
28. Targeting the hedgehog pathway to treat basal cell carcinoma.
Geeraert P; Williams JS; Brownell I
J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
[TBL] [Abstract][Full Text] [Related]
29. A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition.
Biehs B; Dijkgraaf GJP; Piskol R; Alicke B; Boumahdi S; Peale F; Gould SE; de Sauvage FJ
Nature; 2018 Oct; 562(7727):429-433. PubMed ID: 30297801
[TBL] [Abstract][Full Text] [Related]
30. Vismodegib in basal cell carcinoma.
Amaria RN; Bowles DW; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
[TBL] [Abstract][Full Text] [Related]
31. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
[TBL] [Abstract][Full Text] [Related]
32. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
[TBL] [Abstract][Full Text] [Related]
33. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
[TBL] [Abstract][Full Text] [Related]
35. The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells.
Wu Y; Wang Y; Yang XH; Kang T; Zhao Y; Wang C; Evers BM; Zhou BP
Cell Rep; 2013 Oct; 5(1):224-36. PubMed ID: 24075993
[TBL] [Abstract][Full Text] [Related]
36. Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
Giannetti AM; Wong H; Dijkgraaf GJ; Dueber EC; Ortwine DF; Bravo BJ; Gould SE; Plise EG; Lum BL; Malhi V; Graham RA
J Med Chem; 2011 Apr; 54(8):2592-601. PubMed ID: 21438527
[TBL] [Abstract][Full Text] [Related]
37. A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature.
Passarelli A; Galdo G; Aieta M; Fabrizio T; Villonio A; Conca R
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202689
[TBL] [Abstract][Full Text] [Related]
38. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
39. ¹H, ¹³C and ¹⁵N backbone and side-chain resonance assignments of the N-terminal ubiquitin-binding domains of the human deubiquitinase Usp28.
Wen Y; Cui R; Zhang H; Zhang N
Biomol NMR Assign; 2014 Oct; 8(2):251-4. PubMed ID: 23754699
[TBL] [Abstract][Full Text] [Related]
40. Vismodegib.
Meiss F; Andrlová H; Zeiser R
Recent Results Cancer Res; 2018; 211():125-139. PubMed ID: 30069764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
